Sequana Medical announces positive results from CHIHUAHUA,
PRESS RELEASE Phase 1 clinical trial (CHIHUAHUA) demonstrates that single dose of second-generation DSR product (DSR 2.0) is safe and well-tolerated,......
Sequana Medical announces 2022 Full Year Results and 2023
PRESS RELEASEREGULATED INFORMATION09 February 2023, 07:00 CEST alfapump® – successful primary endpoint read-out of North American pivotal POSEIDON study......
Sequana Medical announces grant of additional DSR® patent
PRESS RELEASE Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the......